Healthcare Cost and Utilization for Chimeric Antigen Receptor (CAR)
T-Cell Therapy in the Treatment of Pediatric Acute Lymphoblastic
Leukemia: A Commercial Insurance Claims Database Analysis
Alex Hoover1, Paige Reimche2, Dave
Watson2, Lynn Tanner2, Laura
Gilchrist2,3, Mike Finch2, Yoav H
Messinger2, Lucie M. Turcotte1
Affiliations: 1. Optum Labs Visiting Fellow, University of Minnesota
Medical School, Minneapolis, MN; 2. Children’s Minnesota, Minneapolis,
MN. 3. St. Catherine University, St. Paul, MN.
Funding: This work was supported in part by the NIH-NRSA Research
Fellowship in Translational & Genomic Pediatric Cancer Epidemiology -
T32CA099936 (AH), the National Cancer Institute Grant No. K08CA234232
(LMT); the Pine Tree Apple Classic Fund (LG, YHM); and the Children’s
Cancer Research Fund (LMT).
Corresponding author: Alex Hoover, MD, Division of Pediatric Blood and
Marrow Transplantation, University of Minnesota Medical School, 420
Delaware St SE, Minneapolis, MN 55455; email: hoove231@umn.edu
Abstract word count: 245 words
Main text word count: 1993 words
2 tables, 2 figures included
Keywords: cost, CAR-T, pediatric, ALL
Running head: Cost of CAR-T Therapy in Pediatric ALL
Abbreviations Table